Abstract
Diseases of the central nervous system are among the most devastating to patients and their families. Despite this, treatments for these diseases have lagged behind other therapeutic areas. Although social and economic factors may be partly responsible for the paucity of therapeutic agents, a particularly daunting challenge for CNS drug discovery is the need for compounds to cross the blood brain barrier. Recent analyses of successful drugs have shown that their chemical properties have not changed substantially over the past 40 years while the properties of compounds entering the clinic have become inflated. This property inflation has only exacerbated the challenges of CNS drug discovery as the requirements for delivery to the brain are even more stringent than those for other tissues. New approaches are needed to meet these challenges. In this review, we discuss the merits of fragment based lead discovery and how it may be used to address the challenges of CNS drug discovery. We also summarize compounds discovered by high-throughput screening, substrate evolution and fragment-based lead discovery for well known CNS targets. The results indicate that FBLD may be a key method for discovery of brain penetrable CNS therapeutics.
Keywords: Fragment-based lead discovery, blood brain barrier, central nervous system, Alzheimer's disease, schizophrenia, BACE, GSK3, PDE4
Current Topics in Medicinal Chemistry
Title: Start Small and Stay Small: Minimizing Attrition in the Clinic with a Focus on CNS Therapeutics
Volume: 9 Issue: 18
Author(s): Vicki Nienaber
Affiliation:
Keywords: Fragment-based lead discovery, blood brain barrier, central nervous system, Alzheimer's disease, schizophrenia, BACE, GSK3, PDE4
Abstract: Diseases of the central nervous system are among the most devastating to patients and their families. Despite this, treatments for these diseases have lagged behind other therapeutic areas. Although social and economic factors may be partly responsible for the paucity of therapeutic agents, a particularly daunting challenge for CNS drug discovery is the need for compounds to cross the blood brain barrier. Recent analyses of successful drugs have shown that their chemical properties have not changed substantially over the past 40 years while the properties of compounds entering the clinic have become inflated. This property inflation has only exacerbated the challenges of CNS drug discovery as the requirements for delivery to the brain are even more stringent than those for other tissues. New approaches are needed to meet these challenges. In this review, we discuss the merits of fragment based lead discovery and how it may be used to address the challenges of CNS drug discovery. We also summarize compounds discovered by high-throughput screening, substrate evolution and fragment-based lead discovery for well known CNS targets. The results indicate that FBLD may be a key method for discovery of brain penetrable CNS therapeutics.
Export Options
About this article
Cite this article as:
Nienaber Vicki, Start Small and Stay Small: Minimizing Attrition in the Clinic with a Focus on CNS Therapeutics, Current Topics in Medicinal Chemistry 2009; 9 (18) . https://dx.doi.org/10.2174/156802609790102374
DOI https://dx.doi.org/10.2174/156802609790102374 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CDK5 and MAPT Gene Expression in Alzheimer's Disease Brain Samples
Current Alzheimer Research Preactive Multiple Sclerosis Lesions Offer Novel Clues for Neuroprotective Therapeutic Strategies
CNS & Neurological Disorders - Drug Targets Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Role of Matrix Metalloproteinases in Animal Models of Ischemic Stroke
Current Vascular Pharmacology Development of Radioligands for the Imaging of α7 Nicotinic Acetylcholine Receptors with Positron Emission Tomography
Current Drug Targets Cerebral Ischemia and Angiogenesis
Current Neurovascular Research Conditional Tat Protein Brain Expression in the GT-tg Bigenic Mouse Induces Cerebral Fractional Anisotropy Abnormalities
Current HIV Research Mitochondrial Serine Protease HtrA2/Omi as a Potential Therapeutic Target
Current Drug Targets Inhibition of mTOR Signaling by Quercetin in Cancer Treatment and Prevention
Anti-Cancer Agents in Medicinal Chemistry Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets Potential Roles of HDAC Inhibitors in Mitigating Ischemia-induced Brain Damage and Facilitating Endogenous Regeneration and Recovery
Current Pharmaceutical Design Interaction of Buffalo Brain Cystatin with Serotonin
Current Nanoscience Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls
Current Psychiatry Reviews Sex-Genetic Interaction in the Risk for Cerebrovascular Disease
Current Medicinal Chemistry Editorial [Hot Topic New Clinical Indications of Antipsychotic Medications Guest Editors: Filippo Bogetto and Silvio Bellino]
Current Psychopharmacology Bone Marrow-Derived Mesenchymal Stem Cells Contribute to the Reduction of Amyloid-β Deposits and the Improvement of Synaptic Transmission in a Mouse Model of Pre-Dementia Alzheimer’s Disease
Current Alzheimer Research Meet Our Editorial Board Member
Current Alzheimer Research Conference Report: 181<sup>st</sup> Annual Meeting of the American Association for the Advancement of Science (AAAS), San Jose Convention Center, San Jose, CA, USA February 12-16, 2015
CNS & Neurological Disorders - Drug Targets Pharmacophore Based 3DQSAR of Phenothiazines as Specific Human Butyrylcholinesterase Inhibitors for Treatment of Alzheimer’s Disease
Current Computer-Aided Drug Design Cross Currents in Protein Misfolding Disorders: Interactions and Therapy
CNS & Neurological Disorders - Drug Targets